[Acral erythema occurring after didanosine (Videx) therapy].
Pedailles
S
S
Service de Dermatologie, Hôpital Pasteur, Cherbourg.
Launay
V
V
Surbled
M
M
Sentias
C
C
Bazin
A
A
D000328:Adult; D016049:Didanosine / Q000009:adverse effects* / Q000627:therapeutic use; D004890:Erythema / Q000139:chemically induced*; D005533:Foot Dermatoses / Q000139:chemically induced*; D015658:HIV Infections / Q000188:drug therapy; D006229:Hand Dermatoses / Q000139:chemically induced*; D006801:Humans; D008297:Male; D011358:Product Surveillance, Postmarketing
D016049:Didanosine
Erythème acral survenant après prise de didanosine (Videx).